Sign In
Buy AEZS
$5.72
+0 (+0%)
At Close: Nov 13, 2024
AEZS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aeterna Zentaris Inc. Is Fair to Shareholders
09:19am, Thursday, 14'th Dec 2023
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aeterna Zentaris Inc. (NASDAQ: AEZS) and Ceapro Inc. is fair to Aeterna shareholders. H
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
07:50am, Thursday, 14'th Dec 2023
TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative bioph
Aeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates
10:42am, Wednesday, 09'th Aug 2023
Aeterna Zentaris (AEZS) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $0.87 per share a year ago.
Aeterna Zentaris Reports Second Quarter 2023 Financial Results
08:05am, Wednesday, 09'th Aug 2023
TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commerci
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update
07:30am, Thursday, 13'th Jul 2023
TORONTO, ONTARIO, July 13, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commerci
Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series
08:45am, Wednesday, 05'th Jul 2023
Live moderated video webcast on Thursday, July 13 th at 10:00 AM ET TORONTO, ONTARIO, July 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Compan
Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders
04:05pm, Wednesday, 14'th Jun 2023
TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing
Aeterna Zentaris Reports First Quarter 2023 Financial Results
05:00pm, Tuesday, 09'th May 2023
– Ended the quarter with $ 46 . 6 million in cash, expected to fund operations into 2025
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
07:55am, Wednesday, 05'th Apr 2023
TORONTO, ONTARIO, April 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commerc
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
10:40am, Thursday, 23'rd Mar 2023
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 9.68% and 134.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
08:05am, Thursday, 23'rd Mar 2023
– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025 – Executing strategy to streamline advancement of development programs, build upon growi
TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commerc
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
11:19am, Tuesday, 07'th Feb 2023
Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
08:05am, Tuesday, 10'th Jan 2023
Live video webcast on Thursday , January 19 th at 3 :00 PM ET
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
08:01pm, Tuesday, 21'st Jun 2022 GlobeNewswire Inc.
- Vote to approve share consolidation adjourned to July 6, 2022
